b'Peptide Drug Delivery of Famciclovir,Ganciclovir, Nelfinavir, Rimantadine,Sofosbuvir, and Tipranavir forTreatment of COVID-19:A QSAR StudyLukas SmidtasSponsor: Dr. ManningOne of the key biological characteristics of SARS-CoV-2, as well as several other viruses, is the presence of spike proteins that allow these viruses to penetrate host cells and cause infectious diseases. When the virus approaches a healthy cell to infect, it is the spike proteins that will bring the virus and the cell together for fusion, primarily through a series of conformational changes in surface membrane proteins. Spike proteins are one of the main components that antiviral medications target, primarily as a recognition factor so that the antiviral compound can be effective against infected cells. This QSAR study analyzes different antiviral medications to test their physical and biological effectivity against COVID-19 by incorporating the first two amino acids of a coronavirus spike protein sequence. In this study, the first two amino acids of the COVID-19 spike protein 7L7K, methionine and phenylalanine, was attached to the structures of antiviral medications such as Famciclovir, Ganciclovir, Nelfinavir, Rimantadine, Sofosbuvir, and Tipranavir to examine how effective they can be against COVID-19. Parameters such as octanol-water coefficient LogP, kinase inhibitor activity, protease inhibitor activity, and enzyme inhibitor activity were examined in this study.Arbidol, Pencliclover, Lopinavir, Abacavir, Norvir, and Saquinavir with Met-Phe Spike ProteinKennedy R. DeLucaSponsor: Dr. ManningCOVID-19, first identified in Wuhan, China in December of 2019, has caused over 5 million COVID related deaths. This QSAR study seeks to find an antiviral that successfully binds to a COVID spike protein in order to find new drugs. The peptide pulled from the spike protein sequence is MET-PHE. This peptide was used to test different physical and bioactivity properties when added to different antivirals. This information can assist in the quest to find a successful treatment to complete a full recovery in an infected COVID-19 patient. Results showed that after the addition of the peptide, a select few antivirals showed promise.Peptide Drug Delivery of Amprenavir, Foscarnet, Methisazone, Oseltamivir, Zalcitabine, and Tipranavirfor the Treatment of Covid-19Vraj M. PatelSponsor: Dr. ManningQSAR studies are used investigate the quantitative structure-activity relationships between a virus and antiviral drugs. QSAR was originally developed for nucleoside analogs with anti-HIV activity. The spike protein used for this data is classified as 6XM4, with the last two amino acids Glutamine and Lysine. The antiviral drugs being analyzed are Edoxudine, Telbivudine, Valganciclovir, Vicriviroc, Vidarabine, and Pleconaril. These drugs are used to treat viruses such as HIV and Hepatitis.20'